BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8895752)

  • 1. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
    Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
    Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.
    Shankar S; Vaidyanathan G; Affleck D; Welsh PC; Zalutsky MR
    Bioconjug Chem; 2003; 14(2):331-41. PubMed ID: 12643743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
    Vaidyanathan G; Alston KL; Bigner DD; Zalutsky MR
    Bioconjug Chem; 2006; 17(4):1085-92. PubMed ID: 16848419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods.
    Smellie WJ; Dean CJ; Sacks NP; Zalutsky MR; Garg PK; Carnochan P; Eccles SA
    Cancer Res; 1995 Dec; 55(23 Suppl):5842s-5846s. PubMed ID: 7493357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.
    Arano Y; Wakisaka K; Ohmono Y; Uezono T; Akizawa H; Nakayama M; Sakahara H; Tanaka C; Konishi J; Yokoyama A
    Bioconjug Chem; 1996; 7(6):628-37. PubMed ID: 8950481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
    Foulon CF; Welsh PC; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2001 Oct; 28(7):769-77. PubMed ID: 11578897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factor receptors as molecular targets for cancer diagnosis and therapy.
    Zalutsky MR
    Q J Nucl Med; 1997 Jun; 41(2):71-7. PubMed ID: 9203846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
    Vaidyanathan G; Affleck DJ; Li J; Welsh P; Zalutsky MR
    Bioconjug Chem; 2001; 12(3):428-38. PubMed ID: 11353542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
    Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
    Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
    Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.